TALS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TALS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Talaris Therapeutics's 3-Year RORE % for the quarter that ended in Jun. 2023 was 11.62%.
The industry rank for Talaris Therapeutics's 3-Year RORE % or its related term are showing as below:
The historical data trend for Talaris Therapeutics's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Talaris Therapeutics Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
3-Year RORE % | - | - | - | 17.39 |
Talaris Therapeutics Quarterly Data | |||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
3-Year RORE % | Get a 7-Day Free Trial | - | 24.62 | 17.39 | 18.27 | 11.62 |
For the Biotechnology subindustry, Talaris Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Talaris Therapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Talaris Therapeutics's 3-Year RORE % falls into.
Talaris Therapeutics's 3-Year RORE % for the quarter that ended in Jun. 2023 is calculated as:
3-Year RORE % | = | ( Most Recent EPS (Diluted) | - | First Period EPS (Diluted) ) | / | ( Cumulative EPS (Diluted) for 3-year | - | Cumulative Dividends per Share for 3-year ) |
= | ( -1.79 | - | -1.259 ) | / | ( -4.569 | - | 0 ) | |
= | -0.531 | / | -4.569 | |||||
= | 11.62 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2023 and 3-year before.
Talaris Therapeutics (NAS:TALS) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Thank you for viewing the detailed overview of Talaris Therapeutics's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cariad Chester | director | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Yung H. Chyung | officer: Chief Medical Officer | C/O SCHOLAR ROCK, 620 MEMORIAL DR., 2ND FLOOR, CAMBRIDGE MA 02139 |
Caley Castelein | director | THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104 |
W Bradford Middlekauff | officer: CBO, GC and Secretary | 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922 |
Aaron Kantoff | director | C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH |
Sandeep Chidambar Kulkarni | director, officer: CEO | 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027 |
Kevin Bruce Johnson | officer: Chief Regulatory Officer | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Ryan F. Robinson | officer: Interim CFO | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Parvinder Thiara | director | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Susan Dana Jones | officer: Chief Technology Officer | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Suzanne Ildstad | director, 10 percent owner, officer: Chief Scientific Officer | C/O TALARIS THERAPEUTICS, INC., 93 WORCESTER STREET, SUITE 120, WELLESLEY MA 02481 |
Scott Requadt | director, officer: See Remarks | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Francois Nader | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
From GuruFocus
By GlobeNewswire • 10-17-2023
By Value_Insider Value_Insider • 11-07-2022
By PRNewswire • 08-22-2023
By Marketwired • 08-21-2023
By PurpleRose PurpleRose • 07-11-2022
By GuruFocusNews GuruFocusNews • 07-07-2022
By Business Wire • 06-25-2023
By Marketwired • 07-31-2023
By Marketwired • 10-04-2023
By Marketwired • 06-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.